Dermavant Sciences: Dermavant Showcases New Long-Term Durabi

- Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxis - Tapinarof was well-tolerated

Related Keywords

Boston , Massachusetts , United States , America , American , Laurence Watts , Kostenloser Wertpapierhandel , Aprilw Armstrong , Angela Salerno Robin , Philipm Brown , Program For Tapinarof , Twitter , Drug Administration , Keck School Of Medicine , Dean For Clinical Research In Dermatology , American Academy Of Dermatology , Roivant Sciences , Dermavant Sciences , Linkedin Dermavant Sciences , Annual Meeting , Keck Medicine , Associate Dean , Clinical Research , Keck School , Physician Global Assessment , Psoriasis Area , Severity Index , Dermatology Life Quality Index , Chief Medical Officer , New Drug Application , Prescription Drug User Fee Act , North America , Vice President , Media Relations , Dermavant , Ciences , Howcases , Song , Term , Durability , Tolerability , Data , Rom , Hase , Soaring , Trial , Tapinarof , Cream , Adults , Plaque , Psoriasis , 022 , Nnual , Meeting ,